Brokerages predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report $0.67 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings. The highest EPS estimate is $0.75 and the lowest is $0.62. Teva Pharmaceutical Industries posted earnings per share of $1.06 in the same quarter last year, which would suggest a negative year over year growth rate of 36.8%. The business is expected to announce its next earnings report on Thursday, May 10th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.43 per share for the current year, with EPS estimates ranging from $2.32 to $2.50. For the next fiscal year, analysts anticipate that the company will post earnings of $2.85 per share, with EPS estimates ranging from $2.54 to $3.29. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The company’s revenue for the quarter was down 15.9% compared to the same quarter last year.
Teva Pharmaceutical Industries (TEVA) opened at $18.37 on Friday. Teva Pharmaceutical Industries has a 12-month low of $10.85 and a 12-month high of $34.38. The stock has a market capitalization of $18,860.00, a P/E ratio of -1.06, a price-to-earnings-growth ratio of 1.57 and a beta of 0.65. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86.
In related news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at $876,094.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 7,636 shares of company stock valued at $149,390 in the last three months. 7.10% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the stock. Franklin Resources Inc. increased its position in shares of Teva Pharmaceutical Industries by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after purchasing an additional 6,009,897 shares in the last quarter. Two Sigma Advisers LP acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $118,487,000. Schroder Investment Management Group increased its position in shares of Teva Pharmaceutical Industries by 22.7% during the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after purchasing an additional 1,147,683 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after purchasing an additional 3,429,448 shares in the last quarter. Finally, OppenheimerFunds Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth $69,418,000. 58.22% of the stock is owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.